Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Eyes with Primary Open-Angle Glaucoma: A 36-Month Analysis from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).
Radcliffe Nathan M, Harris Jennifer, Garcia Kristian, Zwick Erin, Chang Robert T, Mbagwu Michael
AI Summary
Standalone OMNI surgery for POAG significantly reduced IOP and/or medication use for up to 36 months, making it a viable MIGS option for sustained pressure and medication reduction.
Abstract
Purpose
To characterize long-term real-world clinical outcomes of standalone canaloplasty and trabeculotomy using the OMNI Surgical System (Sight Sciences) in patients with primary open-angle glaucoma (POAG).
Design
Retrospective, clinical cohort study utilizing the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) data.
Subjects
Patients/eyes in the IRIS Registry with POAG or ocular hypertension with known laterality on or after January 1, 2016 and undergoing standalone canaloplasty and trabeculotomy using the OMNI Surgical System with at least 6 months and up to 36 months of postoperative follow-up were included. Eyes were excluded for prior filtration surgery, trabeculoplasty within 90 days of the OMNI procedure, or concomitant cataract surgery.
Methods/outcome measures: Outcome measures included intraocular pressure (IOP) and glaucoma medication changes postoperatively.
Results
230 eyes in 196 patients were analyzed. Most eyes had moderate (40.0 %) or severe (41.3 %) POAG. Two-thirds (153 of 230) were pseudophakic. Fewer than half of procedures (44.4 %) were performed by glaucoma specialists. Mean baseline IOP was 22.1 (6.4) mmHg and over 36 months of follow-up ranged from 15.1 to 16.7 mmHg (p < 0.0001 at every time point compared to baseline), with average eye-level reductions of 5.6-7.1 mmHg. The mean number of glaucoma medications used at baseline was 2.1 (1.5) and over 36 months ranged from 1.1 to 1.8 medication classes, with statistically significant decreases in utilization through 18 months postoperatively (p ≤ 0.0011) and nonsignificant at months 24 and 36. Eyes with lower baseline IOP (≤18 mmHg) had reductions in medication use through 36 months, and eyes with higher baseline IOP (>18 mmHg) had statistically significant reductions in IOP through 36 months.
Conclusions
Standalone canaloplasty and trabeculotomy provides clinically and statistically significant reductions in IOP through up to 36 months postoperatively. Eyes with lower baseline IOP had long-term glaucoma medication reductions and eyes with higher baseline IOP had statistically significant long-term IOP reductions. Standalone OMNI surgery is a reasonable MIGS option for patients with POAG seeking IOP reduction, medication reduction, or both.
MeSH Terms
Shields Classification
Key Concepts6
Standalone canaloplasty and trabeculotomy using the OMNI Surgical System provides clinically and statistically significant reductions in intraocular pressure (IOP) through up to 36 months postoperatively in patients with primary open-angle glaucoma (POAG).
In eyes with lower baseline intraocular pressure (IOP) (≤18 mmHg) undergoing standalone canaloplasty and trabeculotomy using the OMNI Surgical System, reductions in glaucoma medication use were observed through 36 months.
In eyes with higher baseline intraocular pressure (IOP) (>18 mmHg) undergoing standalone canaloplasty and trabeculotomy using the OMNI Surgical System, statistically significant long-term IOP reductions were observed through 36 months.
Standalone canaloplasty and trabeculotomy using the OMNI Surgical System resulted in mean baseline intraocular pressure (IOP) of 22.1 (6.4) mmHg, which ranged from 15.1 to 16.7 mmHg over 36 months of follow-up (p < 0.0001 at every time point compared to baseline), with average eye-level reductions of 5.6-7.1 mmHg in patients with primary open-angle glaucoma (POAG).
The mean number of glaucoma medications used at baseline for standalone canaloplasty and trabeculotomy using the OMNI Surgical System was 2.1 (1.5), and over 36 months ranged from 1.1 to 1.8 medication classes, with statistically significant decreases in utilization through 18 months postoperatively (p ≤ 0.0011) and nonsignificant at months 24 and 36 in patients with primary open-angle glaucoma (POAG).
Standalone OMNI surgery is a reasonable minimally invasive glaucoma surgery (MIGS) option for patients with primary open-angle glaucoma (POAG) seeking intraocular pressure (IOP) reduction, medication reduction, or both.
Related Articles5
The case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm.
ReviewImplantation of a CyPass Supraciliary Stent Combined With Targeted iStent Trabecular Microbypass Stents in a Phakic Patient With Primary Open-angle Glaucoma.
Case ReportEffectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma.
Clinical TrialFive-Year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.
Cohort StudyMicroinvasive glaucoma surgery: A review of 3476 eyes.
Systematic ReviewIs this article assigned to the wrong chapter(s)? Let us know.